Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06695845 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06695845: Recruiting Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Jazz Pharmaceuticals.
NCT06695845 is a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 200 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06695845, a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Primary Outcome
The Independent Central Review (ICR) assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Conditions Studied
Interventions
- DRUG Zanidatamab
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Florida Cancer Specialists - Lake Nona - Orlando
- Florida Cancer Specialists - North - St. Petersburg
- Florida Cancer Specialists - East - West Palm Beach
Texas
- Texas Oncology - West Texas - Amarillo
- Texas Oncology - DFW - Dallas
- MD Anderson Cancer Center - Houston
- Texas Oncology - San Antonio - San Antonio
Seoul
- Samsung Medical Center - Gangnam-gu
- Seoul National University Hospital - Jongno-gu
- Severance Hospital - Seodaemun-gu
Tennessee
- Tennessee Cancer Specialists - Knoxville
- SCRI Oncology Partners - Nashville
Arizona
- Arizona Oncology Associates, PC - NAHOA - Prescott
Colorado
- Rocky Mountain Cancer Center - Littleton
Illinois
- Affiliated Oncologists - Chicago Ridge
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06695845 shows while recruiting
NCT06695845 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Zanidatamab is the first listed.
NCT06695845 names 20 study sites across 11 states, led by Florida, Texas, Seoul.
Frequently Asked Questions
What is clinical trial NCT06695845 about?
NCT06695845 is a clinical study titled "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors". The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
What is the current status of trial NCT06695845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-01-14. Estimated completion is 2027-12-31.
What conditions does trial NCT06695845 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer.
What interventions are being tested in trial NCT06695845?
The interventions under investigation include: Zanidatamab (DRUG).
Who is sponsoring clinical trial NCT06695845?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06695845 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06695845's enrollment target sits among peer trials
200 362nd of 1224 higher than 841 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI